Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?

Fabry disease (FD) is a rare X-linked disorder caused by a deficiency of lysosomal α-galactosidase A activity. Treatment with recombinant enzyme replacement therapy is available since 2001 and the effects of anti-drug antibodies (ADA) on therapy efficacy and disease outcome in affected patients have...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenders, Malte, Schmitz, Boris, Brand, Stefan-Martin, Brand, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162957/
https://www.ncbi.nlm.nih.gov/pubmed/30268124
http://dx.doi.org/10.1186/s13023-018-0916-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162957/
https://www.ncbi.nlm.nih.gov/pubmed/30268124
http://dx.doi.org/10.1186/s13023-018-0916-1

Ejemplares similares